Literature DB >> 10993799

Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.

J Szebeni1, L Baranyi, S Savay, M Bodo, D S Morse, M Basta, G L Stahl, R Bünger, C R Alving.   

Abstract

Intravenous injection of liposomes can cause significant pulmonary hypertension in pigs, a vasoconstrictive response that provides a sensitive model for the cardiopulmonary distress in humans caused by some liposomal drugs. The reaction was recently shown to be a manifestation of "complement activation-related pseudoallergy" (CARPA; Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, Stahl GL, Bünger R, and Alving CR. Circulation 99: 2302-2309, 1999). In the present study we demonstrate that the composition, size, and administration method of liposomes have significant influence on pulmonary vasoactivity, which varied between instantaneously lethal (following bolus injection of 5 mg lipid) to nondetectable (despite infusion of a 2,000-fold higher dose). Experimental conditions augmenting the pulmonary hypertensive response included the presence of dimyristoyl phosphatidylglycerol, 71 mol% cholesterol, distearoyl phosphatidylcholine, and hemoglobin in liposomes, increased vesicle size and polydispersity, and bolus injection vs. slow infusion. The vasoactivity of large multilamellar liposomes was reproduced with human C3a, C5a, and xenoreactive immunoglobulins, and it correlated with the complement activating and natural antibody binding potential of vesicles. Unilamellar, monodisperse liposomes with 0.19 +/- 0.10 microm mean diameter had no significant vasoactivity. These data indicate that liposome-induced pulmonary hypertension in pigs is multifactorial, it is due to natural antibody-triggered classic pathway complement activation and it can be prevented by appropriate tailoring of the structure and administration method of vesicles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993799     DOI: 10.1152/ajpheart.2000.279.3.H1319

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  39 in total

1.  Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.

Authors:  Raul R Ribeiro; Eliane P Moura; Vitor M Pimentel; Weverton M Sampaio; Sydnei M Silva; Dante A Schettini; Cintia F Alves; Ferdinan A Melo; Wagner L Tafuri; Cynthia Demicheli; Maria N Melo; Frédéric Frézard; Marilene S M Michalick
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

2.  Simple method for preparing poly(ethylene glycol)-surface-conjugated liposome-encapsulated hemoglobins: physicochemical properties, long-term storage stability, and their reactions with O2, CO, and NO.

Authors:  Shahid Rameez; Andre F Palmer
Journal:  Langmuir       Date:  2011-06-16       Impact factor: 3.882

3.  Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo.

Authors:  Okhil K Nag; Vivek R Yadav; Andria Hedrick; Vibhudutta Awasthi
Journal:  Int J Pharm       Date:  2013-02-16       Impact factor: 5.875

4.  Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.

Authors:  Robin Rajan; Manoj K Sabnani; Vikram Mavinkurve; Hilary Shmeeda; Hossein Mansouri; Sandrine Bonkoungou; Alexander D Le; Laurence M Wood; Alberto A Gabizon; Ninh M La-Beck
Journal:  J Control Release       Date:  2017-12-23       Impact factor: 9.776

Review 5.  Group B Streptococcus, phospholipids and pulmonary hypertension.

Authors:  J Curtis; G Kim; N B Wehr; R L Levine
Journal:  J Perinatol       Date:  2011-04       Impact factor: 2.521

6.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Authors:  Jeremy D Heidel; Zhongping Yu; Joanna Yi-Ching Liu; Shyam M Rele; Yongchao Liang; Ryan K Zeidan; Douglas J Kornbrust; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

7.  The Emulsified PFC Oxycyte® Improved Oxygen Content and Lung Injury Score in a Swine Model of Oleic Acid Lung Injury (OALI).

Authors:  Ashraful Haque; Anke H Scultetus; Francoise Arnaud; Leonora J Dickson; Steve Chun; George McNamee; Charles R Auker; Richard M McCarron; Richard T Mahon
Journal:  Lung       Date:  2016-10-04       Impact factor: 2.584

8.  Improved short-term survival with polyethylene glycol modified hemoglobin liposomes in critical normovolemic anemia.

Authors:  Andreas Pape; Harry Kertscho; Jens Meier; Oliver Horn; Mohamed Laout; Max Steche; Mischa Lossen; Alf Theisen; Bernhard Zwissler; Oliver Habler
Journal:  Intensive Care Med       Date:  2008-04-02       Impact factor: 17.440

Review 9.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.